PsychedelicNewsBreaks

FridayFeb 18, 2022 1:42 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Hails Potential of Promising Psychedelic Medicines

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that psychedelic medicine (ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings…” Of the respondents, 18%…

Continue Reading

FridayFeb 18, 2022 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders; the milestone was identified as Year 2 Q2 (iii). According to the transaction agreement, 17,239.5 Cybin class B common shares will be issued to Adelia shareholders when relevant milestones have been met; the class B Shares will be exchangeable for common shares in the capital of Cybin at an exchange rate of 10 to 1. Adelia is working on developing medicinal psychedelics with improved…

Continue Reading

WednesdayFeb 16, 2022 1:27 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough…

Continue Reading

WednesdayFeb 16, 2022 11:36 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the Aegis Virtual Conference. The event will span three days, from Feb 23-25, 2022, with Drysdale’s presentation scheduled to begin at 2 p.m. ET on Thursday, Feb. 24. Interested parties should visit https://ibn.fm/eqPBg to listen to the event and access the webcast. An archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/PrtCB About Cybin Inc. Cybin is a leading ethical…

Continue Reading

TuesdayFeb 15, 2022 3:20 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development

Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects such as the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc., in order to make them more effective. This approach has set the company apart from its peers. A…

Continue Reading

TuesdayFeb 15, 2022 1:19 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has entered a strategic partnership with The Chopra Foundation, a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being. Under the collaboration, The Chopra Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health. Emerging research shows the potential for psychedelic-assisted therapy to improve the quality of life for people suffering with mental illnesses, including those specific indications that Cybin is targeting, such as major depressive…

Continue Reading

MondayFeb 14, 2022 1:52 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is on a mission to revolutionize mental health care. The company has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. “The company is working on turning its Psychedelics to Therapeutics(TM) vision into reality by engineering drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders,” reads a recent article, which contains excerpts…

Continue Reading

ThursdayFeb 10, 2022 1:50 pm

PsychedelicNewsBreaks – Microdose Psychedelic to Host February Molecular Masterclass: The LSD Conference

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, announced that it will be hosting the Molecular Masterclass: LSD Conference next week. Microdose is hosting the event, scheduled for Feb. 17, 2022, in partnership with MindBio Therapeutics. The all-virtual conference is designed to offer a scientific deep dive into the dynamic field of LSD microdosing exploring the potential of LSD at the intersection of drug development and safety, clinical care and applications, law and regulation, business and markets, science and research, and…

Continue Reading

WednesdayFeb 09, 2022 2:26 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Bringing Science-Backed Health Benefits to All, Reframing Psychedelic Conversation

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has sought to capitalize on the ongoing transformation within the mental health sector. The company is positioning itself as the United States’ leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation. This comes as Representative Earl Blumenauer recently circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit terminally ill patients to use psilocybin as part of their treatment without fear of being federally prosecuted. Although the DEA has remained steadfast in…

Continue Reading

WednesdayFeb 09, 2022 12:26 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The patent, granted by the U.S. Patent and Trademark Office, strengthens the proprietary position of Cybin’s CYB004 as a deuterated DMT compound until 2041, covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity. CYB004 is Cybin’s lead investigational proprietary DMT compound and in studies has shown potential efficacy at lower doses while also increasing the duration of drug effect providing a therapeutic profile that may…

Continue Reading